GenScript corporation cpass svnt

Analytical performance of each kit in discriminating SARS-CoV-2 infection.

Cpass Svnt, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass svnt/product/GenScript corporation
Average 90 stars, based on 1 article reviews

cpass svnt - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

genscript c-pas svnt (GenScript corporation)

GenScript corporation genscript c-pas svnt

Genscript C Pas Svnt, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/genscript c-pas svnt/product/GenScript corporation
Average 90 stars, based on 1 article reviews

genscript c-pas svnt - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

cpass svnt kit (GenScript corporation)

GenScript corporation cpass svnt kit

Cpass Svnt Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass svnt kit/product/GenScript corporation
Average 90 stars, based on 1 article reviews

cpass svnt kit - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

cpass® svnt omicron ba.1-rbd (GenScript corporation)

GenScript corporation cpass® svnt omicron ba.1-rbd

Cpass® Svnt Omicron Ba.1 Rbd, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass® svnt omicron ba.1-rbd/product/GenScript corporation
Average 90 stars, based on 1 article reviews

cpass® svnt omicron ba.1-rbd - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

Image Search Results

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance of each kit in discriminating SARS-CoV-2 infection.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques: Infection

Analytical performance for representativeness of neutralizing activity using the pre-defined cut-off values of each immunoassay kit.

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance for representativeness of neutralizing activity using the pre-defined cut-off values of each immunoassay kit.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques: Activity Assay

Titer correlation of the analytical performance of the prediction of neutralizing activity using newly calculated cut-off values determined using Youden’s index.

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Titer correlation of the analytical performance of the prediction of neutralizing activity using newly calculated cut-off values determined using Youden’s index.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques: Activity Assay

Serial kinetics of antibody titers measured with each method: (A) PRNT ND50, (B.) GenScript cPass sVNT, (C) Roche Elecsys Anti-SARS-CoV-2, (D) Roche Elecsys Anti-SARS-CoV2 S, and (E) Abbott AdviseDx SARS-CoV2 IgG II.

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Serial kinetics of antibody titers measured with each method: (A) PRNT ND50, (B.) GenScript cPass sVNT, (C) Roche Elecsys Anti-SARS-CoV-2, (D) Roche Elecsys Anti-SARS-CoV2 S, and (E) Abbott AdviseDx SARS-CoV2 IgG II.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Antibody titers by timeline.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques:

Scatter plot and Pearson’s correlation for each method grouped with acute/convalescent phase. (A) GenScript cPass sVNT, (B) Roche Elecsys Anti-SARS-CoV-2, (C) Roche Elecsys Anti-SARS-CoV2 S, and (D) Abbott AdviseDx SARS-CoV2 IgG II were compared with PRNT, respectively. Each colored line depicts the linear regression model and the surrounding grey-colored area represents the 95% confidence interval.

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Scatter plot and Pearson’s correlation for each method grouped with acute/convalescent phase. (A) GenScript cPass sVNT, (B) Roche Elecsys Anti-SARS-CoV-2, (C) Roche Elecsys Anti-SARS-CoV2 S, and (D) Abbott AdviseDx SARS-CoV2 IgG II were compared with PRNT, respectively. Each colored line depicts the linear regression model and the surrounding grey-colored area represents the 95% confidence interval.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques:

genscript cpass svnt Search Results

Image Search Results